EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia : present and futureYANG, Chih-Hsin.Lung cancer. 2008, Vol 60, issn 0169-5002, S23-S30, SUP2Conference Paper

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancerLIN, Chia-Chi; YANG, Chih-Hsin.Targeted oncology. 2009, Vol 4, Num 1, pp 37-44, issn 1776-2596, 8 p.Article

Gemcitabine-induced acute lipodermatosclerosis-like reactionCHU, Chia-Yu; YANG, Chih-Hsin; CHIU, Hsien-Ching et al.Acta dermato-venereologica. 2001, Vol 81, Num 6, pp 426-428, issn 0001-5555Article

Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantroneYANG, Chih-Hsin; CHEN, Yao-Chang; KUO, Min-Liang et al.Anticancer research. 2003, Vol 23, Num 3B, pp 2519-2523, issn 0250-7005, 5 p.Article

Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non―Small Cell Lung CancerWU, Jenn-Yu; YU, Chong-Jen; CHANG, Yeun-Chung et al.Clinical cancer research (Print). 2011, Vol 17, Num 11, pp 3812-3821, issn 1078-0432, 10 p.Article

O⁶-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancersWU, Pei-Fang; KUO, Kuan-Ting; TSENG, Ham-Min et al.Lung cancer. 2010, Vol 68, Num 3, pp 484-490, issn 0169-5002, 7 p.Article

Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapyHO, Chao-Chi; KUO, Sung-Hsin; HUANG, Pei-Hsin et al.Lung cancer. 2008, Vol 59, Num 1, pp 105-110, issn 0169-5002, 6 p.Article

Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutationsWU, Shang-Gin; YANG, Chih-Hsin; YU, Chong-Jen et al.Lung cancer. 2011, Vol 72, Num 3, pp 333-339, issn 0169-5002, 7 p.Article

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexedCHEN, Chung-Yu; CHANG, Yih-Leong; SHIH, Jin-Yuan et al.Lung cancer. 2011, Vol 74, Num 1, pp 132-138, issn 0169-5002, 7 p.Article

Gefitinib or Carboplatin-Paclitaxel in Pulmonary AdenocarcinomaMOK, Tony S; WU, Yi-Long; NISHIWAKI, Yutaka et al.The New England journal of medicine. 2009, Vol 361, Num 10, pp 947-957, issn 0028-4793, 11 p.Article

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancerSHIH, Jin-Yuan; GOW, Chien-Hung; YU, Chong-Jen et al.International journal of cancer. 2006, Vol 118, Num 4, pp 963-969, issn 0020-7136, 7 p.Article

Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancerWU, Jenn-Yu; SHIH, Jin-Yuan; YANG, Chih-Hsin et al.International journal of cancer (Print). 2010, Vol 126, Num 1, pp 247-255, issn 0020-7136, 9 p.Article

Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancersCHEN, Jo-Pai; LO, Yin; YU, Chong-Jen et al.Lung cancer. 2008, Vol 60, Num 1, pp 92-97, issn 0169-5002, 6 p.Article

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment ResponseWU, Jenn-Yu; WU, Shang-Gin; YANG, Chih-Hsin et al.Clinical cancer research (Print). 2008, Vol 14, Num 15, pp 4877-4882, issn 1078-0432, 6 p.Article

A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancerLIN, Chia-Chi; CHENG, Ann-Lii; HSU, Chih-Hung et al.Anticancer research. 2007, Vol 27, Num 1B, pp 641-645, issn 0250-7005, 5 p.Article

Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatmentYANG, Chih-Hsin; CHEN, Min-Chun; CHENG, Ann-Lii et al.Oncology. 2005, Vol 68, Num 4-6, pp 350-355, issn 0030-2414, 6 p.Article

Phase II study of Combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinomaLU, Yen-Shen; CHIUN HSU; LI, Chi-Cheng et al.Hepato-gastroenterology. 2004, Vol 51, Num 57, pp 815-819, issn 0172-6390, 5 p.Article

First-or Second-line Therapy with Gefitinib Produces Equal Survival in Non-Small Cell Lung CancerWU, Jenn-Yu; YU, Chong-Jen; YANG, Pan-Chyr et al.American journal of respiratory and critical care medicine. 2008, Vol 178, Num 8, pp 847-853, issn 1073-449X, 7 p.Article

High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapyPERNG, Reury-Perng; YANG, Chih-Hsin; HSIA, Te-Chun et al.Lung cancer. 2008, Vol 62, Num 1, pp 78-84, issn 0169-5002, 7 p.Article

Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatmentLIN, Zhong-Zhe; HSU, Chiun; CHANG, Yeun-Chung et al.Lung cancer. 2008, Vol 60, Num 2, pp 215-221, issn 0169-5002, 7 p.Article

Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trialHSU, Chiun; KUO, Sung-Hsin; HU, Fu-Chang et al.Lung cancer. 2008, Vol 62, Num 3, pp 334-343, issn 0169-5002, 10 p.Article

Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trialsKUO, Sung-Hsin; YANG, Chih-Hsin; YU, Chong-Jen et al.Lung cancer. 2005, Vol 48, Num 2, pp 275-280, issn 0169-5002, 6 p.Article

Survival of lung adenocarcinoma patients with malignant pleural effusionWU, Shang-Gin; YU, Chong-Jen; TSAI, Meng-Feng et al.The European respiratory journal. 2013, Vol 41, Num 6, pp 1409-1418, issn 0903-1936, 10 p.Article

Clinical Significance of Thyroid Transcription Factor-1 in Advanced Lung Adenocarcinoma Under Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor TreatmentCHUNG, Kuei-Pin; HUANG, Yen-Tsung; CHANG, Yih-Leong et al.Chest (American College of Chest Physicians). 2012, Vol 141, Num 2, pp 420-428, issn 0012-3692, 9 p.Article

Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutationsWU, Jenn-Yu; WU, Shang-Gin; YANG, Chih-Hsin et al.Lung cancer. 2011, Vol 72, Num 2, pp 205-212, issn 0169-5002, 8 p.Article